Company Overview and News

8
Ferrari enlists Philip Morris veteran Camilleri as next CEO

7h thestar.com.my
New chief: People look into a Ferrari showroom in Warsaw, Poland. Ferrari is now entrusting its future to a longtime food-and-tobacco executive who for decades helped steer the Marlboro brand. — AP
PM MO

8
Ferrari Enlists Philip Morris Veteran Camilleri as Next CEO - Bloomberg

2018-07-21 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PM MO

8
Factbox: The executives replacing Marchionne at FCA, Ferrari, CNH

2018-07-21 reuters
MILAN (Reuters) - Fiat Chrysler (FCA) (FCHA.MI) said on Saturday that boss Sergio Marchionne, 66, would not be returning to work because he was gravely ill.
PM MO

1
Vaping industry decries Trump’s tariffs targeting e-cigarettes

2018-07-20 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
IMBBY RAI ITYBF IMBBF MO

83
Jane's June Dividend Increases And Income - Retirement Accounts

2018-07-19 seekingalpha
This is the fourth month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $1,319.70.
GIS CAT O.PRF WBA ENB OPRF JCI HSY ABBV MMM POL MO IRET.PR DUKH GD IRET.PRC TRV IRET.PRB MAIN CMI ENB RY BNS JNJ TROW VZ WPC ABBV MSFT ADM PFE PM PFBC SCL IRET CTL OXLCM OXLCO TD ETN OXLCN BNS CM MSCA INTC TD IBM IRET.PRCL RY TNTTF LYB MSB O DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL CBL

19
89 Champions, Contenders, And Challengers Rank As Wall St. Dividend Stars For July

2018-07-19 seekingalpha
Champion dividend stocks sustain 25 or more annual dividend increases; Contenders show 10-24; Challengers have 5-9. WallStar selections all show .5% or higher price target upsides.
PM HMLP ETE GLOP ENB ANDX PBFX DKL SUN EBBNF MO ENBBF PEGI TLP NRZ GLOP.PRA GLOP.PRB SRLP ENB TCP ORI SIR PEG HMLP.PRA

9
Philip Morris (PM) Q2 Earnings: Will RRPs Steal the Show?

2018-07-18 zacks
Philip Morris International Inc. (PM - Free Report) is slated to release second-quarter 2018 results on Jul 19, before the opening bell. The company’s earnings have lagged estimates in three of the past four quarters, with an average miss of 1.5%. Well, this renowned tobacco company has been sailing on troubled waters, thanks to declining cigarette shipment volumes, triggered by government regulations to curb tobacco consumption and anti-tobacco campaigns.
HD PM VGR BATS 4162 MO

13
AGNC Investment's Q2 2018 And 7/13/2018 BV Projection (Includes NLY BV Projection)

2018-07-18 seekingalpha
I am projecting AGNC will report a minor decrease in quarterly BV for the second quarter of 2018. Most agency peers will also experience a similar type of BV decrease.
NYMTO ORC CHMI NYMTP CIM AI AI.PRB TWO AGNC AIW TWO.PRA TWO.PRB TWO.PRC MO WMC NRZ AIC NLY.PRECL CYS MITT.PRB MITT.PRA CHMI.PRA MTGE MITT MFA.PRA MFA.PRB CYS.PRA CYS.PRB CIM.PRA IVR.PRA IVR.PRB MFO IVR.PRC DX NLY NLY.PRA NLY.PRD NLY.PRE CIM.PRB NLY.PRC ARR NLY.PRF NLY.PRG MFA HTS IVR DX.PRB NYMT DX.PRA ARR.PRB ARR.PRA

6
10 Dividend Stocks That Will Double Your Money

2018-07-16 investorplace
Is it possible to double your money – quickly – buying safe dividend stocks? You bet. Let me explain how…
EAT HTA TWX MAIN AWR TWC BPL MSCA.CL FRT T AOS MSCA VZ DOV FAF FRT.PRC MO

6
Can Smucker's Shareholder-Friendly Moves Help Revive Stock?

2018-07-16 zacks
The J. M. Smucker Company (SJM - Free Report) remains committed toward rewarding shareholders, evident from its latest dividend hike. Incidentally, management approved a quarterly dividend hike of 9% from 78 cents per share to 85 cents. The new dividend will be paid on Sep 4, 2018 to shareholders of record as on Aug 17. This brings the company’s annualized dividend to $3.40 per share, representing an increase from the previously annualized rate of $3.
POOL GTT PF GMCR MO

1
Tableau: What Makes It So Special?

2018-07-15 seekingalpha
Tableau has seen strong growth over the last twelve months and its growth is poised to continue yet there is still a lack of understanding what makes Tableau so special.
MSFT MO

14
Dividend Champion Spotlight: Altria Group, Inc.

2018-07-15 seekingalpha
Altria is the closest thing to a "legendary" stock. Its performance over the years is unparalleled.
PM BUD KHC AHBIF MO

6
101 Dividend Achievers Yield 2.8% To 9.7% For July

2018-07-14 seekingalpha
Dividend Achiever stocks are distinguished by 10 or more straight years of higher dividends. Some 266 Achiever equities are balanced by sector and capitalization. PFM is their tracking ETF.
IBM HEP TLP EPD SEP MCY TCP VGR APU PPL QCOM MO IVZ

6
101 Dividend Achievers Yield 2.8% To 9.7% For June

2018-07-13 seekingalpha
Dividend Achiever stocks are distinguished by 10 or more straight years of higher dividends. Some 266 Achiever equities are balanced by sector and capitalization. PFM is their tracking ETF.
IBM HEP TLP EPD SEP MCY TCP VGR APU PPL QCOM MO IVZ

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to MO / Altria Group, Inc. on message board site Silicon Investor.

Politics for Pros- moderated Books, Movies, Food, Wine, and Whatever
Left Wing Democratic Porch Tomorrowu0027s News Today
Immunomedics (IMMU) - moderated Qualcomm Moderated Thread - please read rules before posting
Canadian Diamond Play Cafi Anything graphite based, CCB, Zen and hopefully much more.
Gold Price Monitor Microsoft Corp. - Moderated (MSFT)
CUSIP: 02209S103